[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525265":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":31,"centralContacts":32,"locations":42,"responsibleParty":60,"collaborators":31,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":31,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":31,"overallStatus":45,"whyStopped":31,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Fujian Provincial Hospital","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Arocitinib-arm","Evaluation of the efficacy and safety of methylprednisolone combined with abrocitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg\u002Fkg body weight per day in combination with Arocitinib 200 mg daily.",[12],"Drug: Abrocitinib",{"label":14,"type":6,"description":15,"interventionNames":16},"Tofacitinib-arm","Evaluation of the efficacy and safety of methylprednisolone combined with tofacitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg\u002Fkg body weight per day in combination with tofacitinib 10 mg daily.",[17],"Drug: Tofacitinib",[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Abrocitinib","Solu-Medrol® 1 mg\u002Fkg body weight intravenous infusion per day in combination with Arocitinib tablets 200 mg per day for 2 weeks",[9],[25],"Solu-Medrol®",{"type":20,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Tofacitinib","Solu-Medrol® 1 mg\u002Fkg body weight intravenous infusion per day in combination with Tofacitinib tablets 10 mg per day for 2 weeks",[14],[25],null,[33,38],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Chao Ji","CONTACT","+86 18651619908","jichaofy@fjmu.edu.cn",{"name":39,"role":35,"phone":40,"phoneExt":31,"email":41},"Peng Zhang","+86 13645096437","396159837@qq.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Department of Dermatology, the First Affiliated Hospital of Fujian Medical University.","RECRUITING","Fuzhou","Fujian","350000","China","CN",{"type":52,"coordinates":53},"Point",[54,55],119.30611,26.06139,{"lat":55,"lon":54},[58,59],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},{"name":39,"role":35,"phone":40,"phoneExt":31,"email":41},{"type":61,"investigatorFullName":39,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"SPONSOR_INVESTIGATOR","Investigator","100525265","early-phase-1-evaluation-of-the-efficacy-and-safety-of-methylprednisolone-combined-with-the-jak-inhibitors-in-the-treatment-of-toxic-epidermal-necrolysis-100525265",false,"NCT06119490","Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis","Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis: Two-arm, Open, Single-center Study","TEN","Inclusion Criteria:\n\n1. Age 18 and above.\n2. Diagnosed with SJS\u002FTEN according to the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria.\n3. Liver and kidney function is within acceptable ranges.\n4. Blood parameters, including complete blood count, coagulation function, and platelet count, are within acceptable ranges.\n5. Patients must sign an informed consent form, understanding the risks and potential benefits of the treatment.\n6. Patients need to be capable of participating in follow-up visits and treatment plans.\n\nExclusion Criteria:\n\n1. History of allergy to JAK inhibitors.\n2. Pregnant or breastfeeding women.\n3. Severe infectious conditions.\n4. History of central nervous system demyelinating diseases.\n5. History of lymphoproliferative diseases.\n6. Active and latent tuberculosis.\n7. HIV carriers with a CD4+ T cell count lower than (\\\u003C200\u002FmL).\n8. Active HBV\u002FHCV infection.\n9. Coagulation disorders or a tendency for thrombosis.\n10. Significant abnormalities in blood routine indicators.\n11. Liver or kidney dysfunction.","ALL","18 Years","70 Years",{"count":75,"type":76},30,"ESTIMATED","INTERVENTIONAL",[79],"EARLY_PHASE1","To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis",[82],"Toxic Epidermal Necrolysis","2023-11-22",{"date":85,"type":86},"2023-11-28","ACTUAL",{"date":88,"type":86},"2023-07-05",{"date":90,"type":76},"2026-09",{"name":39,"class":6},1]